PriceTargets.com logo

Cardiff Oncology - TROV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.35 As of 04/19/2024 01:00 AM ET
▼ -0.02 (-0.46%)
Get New Cardiff Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TROV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TROV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.35.

This chart shows the closing price for TROV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Cardiff Oncology. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2020Noble FinancialReiterated RatingOutperformMedium
10/3/2019Maxim GroupReiterated RatingBuy$6.00Low
10/2/2019Noble FinancialReiterated RatingBuy$23.00Low
8/28/2019Noble FinancialReiterated RatingBuy$23.00Low
8/9/2019Maxim GroupReiterated RatingBuy$6.00Medium
7/31/2019Maxim GroupSet TargetBuy$6.00N/A
5/24/2019Noble FinancialSet TargetBuy$23.00Low
5/23/2019Maxim GroupSet TargetBuy$8.00Low
5/10/2019Noble FinancialSet TargetBuy$5.00Medium
5/8/2019Maxim GroupSet TargetBuy$8.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cardiff Oncology logo
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $4.35
Low: $4.26
High: $4.57

50 Day Range

MA: $16.75
Low: $1.19
High: $24.71

52 Week Range

Now: $4.35
Low: $0.70
High: $3.46

Volume

606,899 shs

Average Volume

648,892 shs

Market Capitalization

$47.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiff Oncology?

The following sell-side analysts have issued reports on Cardiff Oncology in the last twelve months:
View the latest analyst ratings for TROV.

What is the current price target for Cardiff Oncology?

0 Wall Street analysts have set twelve-month price targets for Cardiff Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiff Oncology in the next year.
View the latest price targets for TROV.

What is the current consensus analyst rating for Cardiff Oncology?

Cardiff Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TROV.

What other companies compete with Cardiff Oncology?

Other companies that are similar to Cardiff Oncology include Dyadic International, JATT Acquisition, Quince Therapeutics, Cortexyme and OKYO Pharma. Learn More about companies similar to Cardiff Oncology.

How do I contact Cardiff Oncology's investor relations team?

Cardiff Oncology's physical mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company's listed phone number is (858) 952-7570 and its investor relations email address is [email protected]. The official website for Cardiff Oncology is www.trovagene.com. Learn More about contacing Cardiff Oncology investor relations.